Nuclidium (DE) GmbH

NUCLIDIUM is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for cancer diagnosis and targeted treatment. With our platform, we can combine flexibly copper radiometals with a variety of highly specific cancer-targeting molecules to develop rapidly novel diagnostic and therapeutic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for patients.